

US Equestrian Names Zomedica's PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians

PulseVet® Shock Wave Device Supports Equine Athletes Ahead of Major International Team Events

ANN ARBOR, MI / July 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is honored to announce that the United States Equestrian Federation (USEF), which regularly competes in FEI Team Competitions, Olympics and Paralympics, has named PulseVet as the Official Shock Wave Therapy Supplier of US Equestrian team veterinarians.

"US Equestrian is pleased to partner with a company that supports our efforts to improve the welfare of our horses and ensure our team veterinarians have access to world-class technology to support their care," said Bill Moroney, CEO of US Equestrian. "PulseVet Shock Wave is known for quality, innovation, and the science of the product, and we are proud to welcome them as an official partner and supplier."

CEO of Zomedica, Larry Heaton, commented, "We are honored to be able to work alongside USEF to help provide optimal care and educational support for every level of equine athlete, including those headed to the Olympics this summer, and we look forward to helping bring home the gold for Team USA."

Zomedica's PulseVet device is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The device delivers a non-invasive treatment modality that utilizes high-energy sound waves to stimulate cells and release healing growth factors in the body that reduce inflammation, increase blood flow, and accelerate bone and soft tissue development.

"We feel privileged to partner with the USEF as their Official Shock Wave Therapy," commented Trudy Gage, Vice President of Equine Sales and Client Education. "Zomedica and USEF share a commitment to provide the best possible care for horses at every level of training and competition, whether that be rehabilitation from an injury or maintenance to stay at peak performance."

PulseVet's electro-hydraulic shock wave technology has been clinically proven to treat tendon, ligament, and muscle injuries; osteoarthritis; degenerative joint disease; navicular syndrome; chronic back and neck pain; fractures; and wounds. Electro-hydraulic shock wave continues to be the most researched type of shock wave in the veterinary industry.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

Follow Zomedica

- **Email Alerts:** <http://investors.zomedica.com>
- **LinkedIn:** <https://www.linkedin.com/company/zomedica>
- **Facebook:** <https://m.facebook.com/zomedica>
- **X (formerly Twitter):** <https://twitter.com/zomedica>
- **Instagram:** https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to market size, economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our

business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on [accesswire.com](https://www.accesswire.com)